Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ruxolitinib, often in combination with corticosteroids, and reviews the study ...
In 2021, Incyte's oral JAK inhibitor Jakafi (ruxolitinib) became the first treatment for steroid-refractory acute GvHD in adults and children 12 years and older. Jakafi is Incyte's biggest seller ...
and Incyte’s Jakafi (ruxolitinib) that are used for the acute stages of GVHD. There are roughly 5,000 bone marrow transplants carried out every year in the US, often used to treat blood cancers ...
Ruxolitinib remains a key treatment for MF and PV, but resistance and discontinuation challenges persist due to genetic mutations and disease progression. The MANIFEST-2 trial showed pelabresib ...
The single-arm, third-line trial enrolled 66 adults with acute GvHD with gastrointestinal involvement ... rates in patients who didn’t respond to ruxolitinib, the JAK inhibitor that Incyte ...
Hosted on MSN17d
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame. The ...
No serious adverse events were reported. Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic ...
Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting ...
“GvHD remains a significant challenge and source ... who have failed earlier treatment lines, corticosteroids and ruxolitinib. MaaT013 introduces a novel therapeutic approach by restoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback